BioVie announced promising results from the ADDRESS-LC trial assessing the potential impact of the drug bezisterim on cognitive impairment/brain fog and fatigue in people with Long Covid.
Solve fought for the inclusion of Long Covid and ME/CFS in the Congressionally Directed Medical Research Programs (CDMRP) that funded the trial, and also assisted with ADDRESS-LC trial recruitment.
For more details, read the press release here and watch the webinar explaining the results here.
Stay tuned for our in-depth summary of the trial results in an upcoming edition of our Solve Science Spotlight.
